Anti-interleukin-17 (IL-17) therapy has been used in various autoimmune diseases. However, the efficacy is unexpectedly limited in several IL-17-associated diseases, and the mechanism of limited efficacy remains unclear. Here, we show that a molecular complex containing the adaptor molecule Act1 and tyrosine phosphatase SHP2 mediated autonomous IL-17R signaling that accelerated and sustained inflammation. SHP2, aberrantly augmented in various autoimmune diseases, was induced by IL-17A itself in astrocytes and keratinocytes, sustaining chemokine production even upon anti-IL-17 therapies. Mechanistically, SHP2 directly interacted with and dephosphorylated Act1, which replaced Act1-TRAF5 complexes and induced IL-17-independent activation of IL-17R signaling. Genetic or pharmacologic inactivation of SHP2, or blocking Act1-SHP2 interaction, paralyzed both IL-17-induced and IL-17-independent signaling and attenuated primary or relapsing experimental autoimmune encephalomyelitis. Therefore, Act1-SHP2 complexes mediate an alternative pathway for autonomous activation of IL-17R signaling, targeting which could be a therapeutic option for IL-17-related diseases in addition to current antibody therapies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.immuni.2023.06.012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
IL-17A-Induced Redox Imbalance and Inflammatory Responses in Mice Lung via Act1-TRAF6-IKBα Signaling Pathway: Implications for Lung Disease Pathogenesis.
Inflammation
November 2024
Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER) - Raebareli, Transit Campus, Bijnour-Sisendi Road, Sarojini Nagar, Lucknow, 226002, Uttar Pradesh, India.
IL-17A is a potent proinflammatory cytokine that plays a crucial role in the pathogenesis of various lung diseases. This study focused on the evaluation of the role of IL-17 receptor signaling through one-week intranasal exposure of IL-17A in lung tissues of BALB/c mice. IL-17A triggered inflammatory responses in the mice lungs and led to changes in the morphological alveolar arrangements.
View Article and Find Full Text PDFDeep hematologic response to RD treatment in patients with multiple myeloma is associated with overexpression of IL-17R in CD138+ plasma cells.
Sci Rep
October 2024
Department of Hematology and Transplantology, Pomeranian Medical University, 71-252, Szczecin, Poland.
Article Synopsis
- Lenalidomide (LEN) is an effective immunomodulatory drug for multiple myeloma (MM), but patients often develop resistance and relapse over time.
- This study aimed to identify molecular pathways linked to a strong and lasting response to LEN treatment in newly diagnosed MM patients who reached very good partial remission after LEN and dexamethasone therapy.
- Key findings included increased gene expression related to epigenetic mechanisms and immune response, particularly the overexpression of the IL-17 receptor, suggesting potential targets for future therapies to improve the effectiveness of LEN-based treatments.
IL-17A-neutralizing antibody ameliorates inflammation and fibrosis in rosacea by antagonizing the CXCL5/CXCR2 axis.
FASEB J
October 2024
Clinical Medical College, North China University of Science and Technology, Tangshan, China.
Article Synopsis
- Rosacea is a chronic skin condition that can lead to fibrosis, but the detailed mechanisms of this fibrosis, especially in later stages, are not well understood.
- The study investigated the role of IL-17A-neutralizing antibodies in treating rosacea-like lesions in mice, finding they helped reduce skin damage and inflammation.
- Results showed that these antibodies decreased several inflammatory and fibrosis-related factors, indicating they may effectively inhibit processes that contribute to rosacea-related skin issues.
Effect of interleukin-17A on inflammatory mediator production in interleukin-1β-stimulated human dental pulp fibroblasts.
Eur J Oral Sci
October 2024
Department of Regenerative Dental Medicine, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
In response to pro-inflammatory cytokines such as interleukin (IL)-1β, dental pulp fibroblasts produce various inflammatory mediators, including IL-6, IL-8, CC chemokine ligand 20 (CCL20), and CXC chemokine ligand 10 (CXCL10), leading to the progression of pulpitis. IL-17/IL-17A (IL-17A) is a pro-inflammatory cytokine secreted by T helper (Th) 17 cells following their recruitment to inflamed sites; however, the roles of IL-17A during pulpitis remain unclear. The purpose of this study was to investigate the effect of IL-17A on IL-6, IL-8, CCL20 and CXCL10 production by human dental pulp fibroblasts (HDPFs) in vitro.
View Article and Find Full Text PDFRole and functional mechanisms of IL‑17/IL‑17R signaling in pancreatic cancer (Review).
Oncol Rep
November 2024
Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100730, P.R. China.
Article Synopsis
- Interleukin-17 (IL-17) is a special protein made by certain immune cells that helps the body fight off infections and diseases but can also affect tumors in different ways.
- Pancreatic ductal adenocarcinoma (PDAC) is a very common and tough type of pancreatic cancer that often resists treatments because of its unique environment.
- The article talks about how IL-17 interacts with this cancer and explores new ways doctors might target IL-17 to treat PDAC more effectively.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!